← Back

Wire · opportunities

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Published

18 August 2026

Topic

opportunities

Sectors

Medtech

Geography

United States

Source

Read at biospace.com

Verified

Fusion42 · 18 August 2026 · Fusion42 review

Co-Diagnostics' Chief Commercialization Officer participated in a Utah-based medical devices roundtable discussing industry innovations, highlighting the company's FDA 510(k) submission for its PCR Flu A/B & RSV multiplex test on the Co-Dx PCR Pro® instrument aimed at point-of-care diagnostics.

This Wire brief sits within Fusion42's coverage of Medtech.

◆ The Wire takeaway

You face a near-term regulatory gate for your molecular diagnostic platform with Co-Diagnostics advancing FDA clearance. Prepare now for commercial roll-out if your product is similar or complementary to their point-of-care PCR tests.

Coverage

1 source · 18 Aug 2026

Related on Wire

Topics

Medtechmedical-devicesregulatory-filingdiagnosticsFDA-510kpoint-of-care